Crispr Therapeutics (NASDAQ:CRSP) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, January 1st, BidAskClub reports.
CRSP has been the topic of a number of other reports. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Goldman Sachs Group raised their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, Chardan Capital restated a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $71.38.
Crispr Therapeutics stock opened at $58.33 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The company has a market cap of $3.29 billion, a PE ratio of -16.96 and a beta of 3.20. Crispr Therapeutics has a 12 month low of $29.34 and a 12 month high of $74.00. The company has a fifty day moving average price of $65.14 and a two-hundred day moving average price of $52.14.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Equities research analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. Company insiders own 21.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in CRSP. BNP Paribas Arbitrage SA acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $41,000. Aperio Group LLC acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $153,000. Swiss National Bank lifted its holdings in shares of Crispr Therapeutics by 28.6% during the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock valued at $2,289,000 after buying an additional 10,800 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $466,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is a stock buyback?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.